Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.

RTS,S/AS01(E) is the lead candidate pre-erythrocytic malaria vaccine. In Phase IIb field trials the safety profile was acceptable and the efficacy was 53% (95%CI 31%-72%) for protecting children against clinical malaria caused by P. falciparum. We studied CS-specific T cell responses in order to ide...

Full description

Bibliographic Details
Main Authors:	Ally Olotu, Philippe Moris, Jedidah Mwacharo, Johan Vekemans, Domtila Kimani, Michel Janssens, Oscar Kai, Erik Jongert, Marc Lievens, Amanda Leach, Tonya Villafana, Barbara Savarese, Kevin Marsh, Joe Cohen, Philip Bejon
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3188575?pdf=render

Similar Items

A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E.
by: Francis M Ndungu, et al.
Published: (2012-01-01)

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.
by: Ally Olotu, et al.
Published: (2014-01-01)

Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).
by: Selidji T Agnandji, et al.
Published: (2011-04-01)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01 in 5 to 17 Month Old Kenyan and Tanzanian Children.
by: John Lusingu, et al.
Published: (2010-01-01)

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
by: John Lusingu, et al.
Published: (2010-11-01)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01 in 5 to 17 Month Old Kenyan and Tanzanian Children.
by: John Lusingu, et al.
Published: (2010-01-01)

Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy
by: Carlota Dobaño, et al.
Published: (2019-05-01)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children
by: John Lusingu, et al.
Published: (2010-01-01)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children
by: John Lusingu, et al.
Published: (2010-01-01)

T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children.
by: Daniel Ansong, et al.
Published: (2011-04-01)

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.
by: Bertrand Lell, et al.
Published: (2009-10-01)

Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.
by: Mohammad Zeeshan, et al.
Published: (2012-01-01)

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
by: John N Waitumbi, et al.
Published: (2009-11-01)

Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya.
by: Frances Ibison, et al.
Published: (2012-01-01)

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children
by: Lievens Marc, et al.
Published: (2011-08-01)

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.
by: Mark E Polhemus, et al.
Published: (2009-07-01)

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa
by: Macete Eusebio, et al.
Published: (2011-08-01)

Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine
by: Carter Terrell, et al.
Published: (2011-08-01)

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
by: Juliette Fortpied, et al.
Published: (2020-06-01)

Correction: Randomized Controlled Trial of RTS,S/AS02 and RTS,S/AS01 Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children.
by: Seth Owusu-Agyei, et al.
Published: (2010-01-01)

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
by: Seth Owusu-Agyei, et al.
Published: (2009-10-01)

Correction: Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
by: Seth Owusu-Agyei, et al.
Published: (2010-01-01)

Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.
by: Christian F Ockenhouse, et al.
Published: (2015-01-01)

The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.
by: Michael T White, et al.
Published: (2013-01-01)

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi
by: Griffin J. Bell, et al.
Published: (2020-06-01)

A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01E on blood stage immunity in young Kenyan children [version 1; peer review: 1 approved, 2 approved with reservations]
by: Francis M. Ndungu, et al.
Published: (2019-03-01)

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care
by: Vekemans Johan, et al.
Published: (2011-08-01)

The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan.
by: Roly Gosling, et al.
Published: (2016-04-01)

A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses
by: Suresh Pallikkuth, et al.
Published: (2020-04-01)

Serological evidence of discrete spatial clusters of Plasmodium falciparum parasites.
by: Philip Bejon, et al.
Published: (2011-01-01)

Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis
by: Sidhartha Chaudhury, et al.
Published: (2017-08-01)

Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission.
by: Alan Brooks, et al.
Published: (2012-01-01)

Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?
by: Arora N, et al.
Published: (2021-03-01)

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02<sub>D</sub> malaria vaccine in infants living in a malaria-endemic region
by: Abdulla Salim, et al.
Published: (2013-01-01)

Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children.
by: Anne Liljander, et al.
Published: (2011-01-01)

Monoclonal Antibodies against Plasmodium falciparum Circumsporozoite Protein
by: Min Zhang, et al.
Published: (2017-08-01)

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
by: Robert A. van den Berg, et al.
Published: (2017-05-01)

Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite <it>Plasmodium falciparum</it>
by: Clement Frederic, et al.
Published: (2012-11-01)

RTS,S/AS01 Malaria Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized Controlled Trial in Malawi
by: Larry Han, et al.
Published: (2017-08-01)

Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.
by: Kavita Gandhi, et al.
Published: (2014-01-01)